GT Biopharma (GTBP) to Post Quarterly Earnings on Thursday

GT Biopharma (NASDAQ:GTBP) is expected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect GT Biopharma to post earnings of ($0.08) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

GT Biopharma (NASDAQ:GTBP) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03). On average, analysts expect GT Biopharma to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

GT Biopharma Price Performance

GTBP stock opened at $0.31 on Wednesday. GT Biopharma has a one year low of $0.26 and a one year high of $1.77. The stock has a market cap of $13.87 million, a price-to-earnings ratio of -0.05 and a beta of 0.90. The company has a fifty day moving average price of $0.40 and a two-hundred day moving average price of $0.43.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on GTBP shares. Wall Street Zen upgraded shares of GT Biopharma to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GT Biopharma in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

About GT Biopharma

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).